Sjögren's syndrome classification: Difference between revisions
Created page with "__NOTOC__ {{Sjögren's syndrome}} {{CMG}} ==Overview== ==Classification== Revised Classification Criteria for Sjogren's Syndrome<ref>Ann Rheum Dis 2002; 61: 54-558</ref> A..." |
m Categories |
||
Line 50: | Line 50: | ||
:[[Graft-versus-host disease]] | :[[Graft-versus-host disease]] | ||
:Use of [[anticholinergic]] drugs (since a time shorter than 4-fold life of the drug) | :Use of [[anticholinergic]] drugs (since a time shorter than 4-fold life of the drug) | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category: | |||
[[Category:Immunology]] | |||
[[Category:Rheumatology]] | [[Category:Rheumatology]] | ||
Revision as of 15:05, 23 June 2016
Sjögren's syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Sjögren's syndrome classification On the Web |
American Roentgen Ray Society Images of Sjögren's syndrome classification |
Risk calculators and risk factors for Sjögren's syndrome classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Classification
Revised Classification Criteria for Sjogren's Syndrome[1]
A. Ocular symptoms: a positive response to at least one of the following questions:
- 1. Have you had daily, persistent, troublesome dry eyes for more than 3 months?
- 2. Do you have a recurrent sensation of sand or gravel in the eyes?
- 3. Do you use tear substitutes more than 3 times a day?
B. Oral symptoms: a positive response to at least one of the following questions:
- 1. Have you had a daily feeling of dry mouth for more than 3 months?
- 2. Have you had recurrently or persistently swollen salivary glands as an adult?
- 3. Do you frequently drink liquids to aid in swallowing dry food?
C. Ocular signs- that is, objective evidence of ocular involvement defined as a positive result for at least one of the following two tests:
- 1. Schirmer's test, performed without anaesthesia ( ≦5 mm in 5 minutes )
- 2. Rose bengal score or other ocular dye score ( ≧4 according to van Bijsterveld's scoring system )
D. Histopathology: In minor salivary glands (obtained through normal-appearing mucosa) focal lymphocytic sialoadenitis, evaluated by an expert histopathologist, with a focus score ≧1, defined as a number of lymphocytic foci (which are adjacent to normal-appearing mucous acini and contain more than 50 lymphocytes) per 4 mm2 of glandular tissue.
E. Salivary gland involvement: objective evidence of salivary gland involvement defined by a positive result for at least one of the following diagnostic tests:
- 1. Unstimulated whole salivary flow ( ≦ 1.5 ml in 15 minutes )
- 2. Parotid sialography showing the presence of diffuse sialectasias (punctate, cavitary,or destructive pattern ), without evidence of obstruction in the major ducts.
- 3. Salivary scintigraphy showing delayed uptake, reduced concentration and/or delayed excretion of tracer
F. Autoantibodies: presence in the serum of the following autoantibodies:
- 1. antibodies to Ro(SSA) or La(SSB) antigens, or both
Revised rules for classification
For primary SS
In patients without any potentially associated disease, primary SS may be defined as follows:
- a. The presence of any 4 of the 6 items is indicative of primary SS, as long as either item 4 (Histopathology) or 6 (Serology) is positive.
- b. The presence of any 3 of the 4 objective criteria items (that is, items 3, 4, 5, 6)
- c. The classification tree procedure represents a valid alternative method for classification, although it should be more properly used in clinical-epidemiological survey.
For secondary SS
In patients with a potentially associated disease (for instance, another well defined connective tissue disease), the presence of item 1 or item 2 plus any two from among items 3, 4, and 5 may be considered as indicative of secondary SS.
Exclusive criteria
- Past head and neck radiation therapy
- Hepatitis C infection
- Acquired immunodeficiency syndrome (AIDS)
- Pre-existing lymphoma
- Sarcoidosis
- Graft-versus-host disease
- Use of anticholinergic drugs (since a time shorter than 4-fold life of the drug)
References
- ↑ Ann Rheum Dis 2002; 61: 54-558